| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | HSKA | Common Stock | Award | $0 | +44.5K | +232.57% | $0.00 | 63.6K | Jun 13, 2023 | Direct | F1, F2 |
| transaction | HSKA | Common Stock | Award | $0 | +4.06K | +6.38% | $0.00 | 67.6K | Jun 13, 2023 | Direct | F3 |
| transaction | HSKA | Common Stock | Disposed to Issuer | -$8.12M | -67.6K | -100% | $120.00 | 0 | Jun 13, 2023 | Direct | F4 |
Anthony Providenti is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
| Id | Content |
|---|---|
| F1 | Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 31, 2023, by and among the Issuer, Antech Diagnostics, Inc., a California corporation ("Acquiror"), Helsinki Merger Sub LLC, a Delaware limited liability company and a wholly-owned subsidiary of Acquiror, and, solely for purposes of Section 9.15 of the Merger Agreement, Mars, Incorporated, a Delaware corporation, these shares of performance-based restricted stock of the Issuer were fully accelerated assuming maximum level of performance immediately prior to the effectiveness of the merger. |
| F2 | Includes 396 shares of common stock of the Issuer purchased under the Issuer's employee stock purchase plan on May 26, 2023 and 11,000 shares of common stock of the Issuer originally reported as restricted stock. |
| F3 | Pursuant to the Merger Agreement, these performance-based restricted stock units were fully accelerated assuming target level of performance immediately prior to the effectiveness of the merger. |
| F4 | Disposed of pursuant to the Merger Agreement in exchange for cash consideration of $120.00 per share of common stock of the Issuer on the effective date of the merger. |